Piper Sandler Upgrades Teva Pharmaceutical Indus to Neutral, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has upgraded Teva Pharmaceutical Industries (NYSE:TEVA) from Underweight to Neutral and increased the price target from $8 to $12.
January 03, 2024 | 9:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva Pharmaceutical's stock rating has been upgraded by Piper Sandler from Underweight to Neutral, with a raised price target from $8 to $12, indicating a more favorable outlook.
Upgrades by analysts typically lead to a positive short-term reaction in the stock market as they suggest a better-than-previously-expected performance or valuation. The increase in price target further supports this positive outlook, potentially leading to increased investor confidence and a rise in stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100